Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin
Description
With new governments both side of the pond, capital markets picking up, and some geopolitical overhang, there’s a mixed feast for biotech, with a net trend to the positive, says Sidley Austin’s Robert Darwin, who specializes in global M&A and private equity for life sciences and healthcare companies and investors. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Darwin, who is based in London, discussed the consequences for biotech of the changing forces as we enter 2025: the new Labour government’s recently announced budget, the incoming Trump administration, the improving outlook for the markets, and the ongoing — if not mounting — tensions between the U.S. and China. Across each of these is a considerable amount of uncertainty, but the pluses and minuses add up to net positive outlook, he believes.
This episode of The BioCentury Show was sponsored by Cytiva.
View full story: https://www.biocentury.com/article/654182
#biotech #biopharma #pharma #lifescience #deals
00:00 – Introduction
01:49 – U.K.’s Place in Global Biotech
09:41 – Trump & Biotech
17:32 – Deals in 2025
31:57 – Private Equity in Biotech
United States
